Sichuan Huiyu Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2010-10-12
- Employees
- 1.3K
- Market Cap
- -
- Website
- http://www.huiyupharma.com
Clinical Trials
13
Active:0
Completed:4
Trial Phases
2 Phases
Phase 1:8
Not Applicable:5
Drug Approvals
1
PHILIPPINES:1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Phase 1
8 (61.5%)Not Applicable
5 (38.5%)A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors
Not Applicable
Not yet recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: HY05350 for injection
- First Posted Date
- 2025-07-24
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Sichuan Huiyu Pharmaceutical Co., Ltd
- Target Recruit Count
- 262
- Registration Number
- NCT07083323
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China
A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors
Not Applicable
Not yet recruiting
- Conditions
- Solid Tumor
- Interventions
- Drug: Test product HY0001a for injection
- First Posted Date
- 2025-07-16
- Last Posted Date
- 2025-07-16
- Lead Sponsor
- Sichuan Huiyu Pharmaceutical Co., Ltd
- Target Recruit Count
- 261
- Registration Number
- NCT07069062
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China
Human Bioequivalence Study of Liposomal Amphotericin B for Injection
Not Applicable
Recruiting
- Conditions
- Invasive Fungal InfectionsNeutropenic FeverVisceral Leishmaniasis
- Interventions
- Drug: Test product (Liposomal amphotericin B for injection, Sichuan Huiyu Pharmaceutical Co., Ltd.)Drug: Reference product (AmBisome®, Astellas Pharma US Inc.)
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Sichuan Huiyu Pharmaceutical Co., Ltd
- Target Recruit Count
- 42
- Registration Number
- NCT06983665
- Locations
- 🇨🇳
Jinan Central Hospital, No.105, Jiefang Road,, Jinan, Shandong, China
Human Bioequivalence Study of Amphotericin B Liposome for Injection
Not Applicable
Recruiting
- Conditions
- Invasive Fungal InfectionsNeutropenic FeverVisceral Leishmaniasis
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Sichuan Huiyu Pharmaceutical Co., Ltd
- Target Recruit Count
- 42
- Registration Number
- NCT06977490
- Locations
- 🇨🇳
Jinan Central Hospital, No.105, Jiefang Road,, Jinan, Shandong, China
Bioequivalence Study of Ferric Carboxymaltose Injection in Healthy Chinese Participants
Phase 1
Completed
- Conditions
- Healthy Adult
- Interventions
- Drug: Ferric Carboxymaltose Injection [Injectafer®]
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Sichuan Huiyu Pharmaceutical Co., Ltd
- Target Recruit Count
- 84
- Registration Number
- NCT06895993
- Locations
- 🇨🇳
Phase I clinical trial unit of the First Hospital of Jilin University, Changchun, Jilin, China
- Prev
- 1
- 2
- 3
- Next
News
No news found